Insulin Aspart
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Insulin Aspart: From Diabetes Mellitus to Permanent Neonatal Diabetes Mellitus
One-Sentence Summary
Insulin aspart is a rapid-acting insulin analogue whose established use is glycaemic control in diabetes mellitus. Within this evidence pack, the TxGNN model’s top-ranked prediction (Type 1 Diabetes Mellitus, 99.95%) is not a genuine repurposing signal — the evidence pack’s own annotations confirm this is already an original approved indication for insulin aspart, surfaced only due to a data gap in
original_indications. The strongest genuine repurposing candidate is Permanent Neonatal Diabetes Mellitus (PNDM) (99.55%), a rare monogenic disease supported by direct mechanistic reasoning and 1 review-level publication, though currently no clinical trials specifically target this population.
⚠ Data Quality Note
Before reading further: this evidence pack lists “type 1 diabetes mellitus” as the #1-ranked prediction with the strongest evidence (8 Phase 3/4 trials, 20 publications). This is not a repurposing candidate. The pack’s own repurposing_rationale field explicitly states T1D is one of insulin aspart’s original approved indications, and its appearance as a “prediction” reflects a data gap (original_indications: []) rather than a real new-use signal. It is excluded from this report’s primary recommendation to avoid misleading readers. Several lower-ranked candidates (autoimmune oophoritis, opsismodysplasia, stiff person syndrome variants, and both lipodystrophy entries) are similarly flagged in the pack as likely knowledge-graph co-occurrence artefacts or, in the case of lipodystrophy, reverse-causality errors (insulin injection is a known cause of localized lipodystrophy, not a treatment for it). These are excluded here as well.
This report instead focuses on Permanent Neonatal Diabetes Mellitus (rank 5), the highest-ranked candidate with an actual, coherent mechanistic and evidentiary basis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diabetes Mellitus (Type 1/Type 2) — inferred from the pack’s own rationale annotations; original_indications and original_moa are recorded as data gaps and not independently confirmed here |
| Predicted New Indication | Permanent Neonatal Diabetes Mellitus (PNDM) |
| TxGNN Prediction Score | 99.55% (rank 5556 among all predictions) |
| Evidence Level | L3 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (original_moa: [Data Gap]). Based on established pharmacology, insulin aspart is a rapid-acting human insulin analogue that binds the insulin receptor to promote peripheral glucose uptake and suppress hepatic glucose output.
PNDM is typically caused by mutations in KCNJ11, ABCC8, or INS, resulting in an absolute deficiency of endogenous insulin secretion from infancy — mechanistically identical to the insulin deficiency insulin aspart already treats in Type 1 diabetes. The rapid onset/offset kinetics of insulin aspart are also practically well-suited to the frequent, small-volume dosing or pump-based delivery typically required in neonatal and paediatric care.
Insulin replacement is already standard clinical practice for PNDM. What this evidence pack captures, however, is that direct trial-level evidence specific to PNDM is absent — the single supporting publication is a general review rather than a controlled study, so the mechanistic case is strong but the documented evidence base is thin.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28527303 | 2017 | Review | Diabetes Research and Clinical Practice | Reviews insulin usage in neonatal diabetes mellitus, with a focus on continuous subcutaneous insulin infusion (CSII) as management for this rare disorder |
Australia Market Information
No ARTG entries were found for insulin aspart in this evidence pack (total_licenses: 0), and market status is recorded as Not Marketed. Confirmation of current TGA/ARTG registration status should be verified directly against the TGA database before any clinical decision-making, as this may reflect a data collection gap rather than genuine absence from the Australian market (insulin aspart products are widely marketed internationally).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. (Key warnings, contraindications, and drug interaction data were not available in this evidence pack.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale:
- The insulin-deficiency mechanism directly supports insulin replacement in PNDM, and this is already accepted clinical practice — but the evidence pack contains only one indirect review, no PNDM-specific clinical trials, and no confirmed Australian market/ARTG registration for insulin aspart.
To proceed, the following is needed:
- Verification of current TGA/ARTG registration status for insulin aspart (the “0 ARTG entries / Not Marketed” result should be confirmed, not assumed correct)
- TFDA/TGA Product Information for formal safety, contraindication, and interaction data (all currently data gaps)
- Confirmed original indications and MOA documentation for insulin aspart (currently data gaps in this pack)
- Direct clinical or observational evidence in PNDM populations, beyond the single available review article
- Re-validation of the TxGNN pipeline’s handling of already-approved indications (e.g. T1D here) so they are not presented as novel repurposing candidates in future evidence packs
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.